Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

BACKGROUND: Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking. METHODS: This was a prospective, single-arm phase 3b study...

Descripción completa

Detalles Bibliográficos
Autores principales: Heidenreich, Axel, Gillessen, Silke, Heinrich, Daniel, Keizman, Daniel, O’Sullivan, Joe M., Carles, Joan, Wirth, Manfred, Miller, Kurt, Reeves, John, Seger, Monica, Nilsson, Sten, Saad, Fred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322274/
https://www.ncbi.nlm.nih.gov/pubmed/30612558
http://dx.doi.org/10.1186/s12885-018-5203-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322274/
https://www.ncbi.nlm.nih.gov/pubmed/30612558
http://dx.doi.org/10.1186/s12885-018-5203-y

Ejemplares similares